Advertisement

Topics

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)

2014-08-27 03:54:46 | BioPortfolio

Summary

Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Prostate Cancer

Intervention

CC-4047

Location

University of Colorado Health Science Center
Denver
Colorado
United States
80220-3706

Status

Completed

Source

Celgene Corporation

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:54:46-0400

Clinical Trials [2220 Associated Clinical Trials listed on BioPortfolio]

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment

RATIONALE: CC-4047 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of CC-4047 in treating pa...

Expanded Access for CC-4047

This is an expanded access program (EAP) for eligible participants designed to provide access to CC-4047.

Efficacy and Safety Study of CC-4047 to Treat Advanced Soft Tissue Sarcoma

The purpose of the study is to determine the safety and efficacy of single agent CC-4047 in patients with advanced soft tissue sarcomas who have relapsed or are refractory to prior antican...

CC-4047 (Pomalidomide) for Graft vs. Host Disease

This study will test the safety and effectiveness CC-4047 (pomalidomide) in patients with advanced, steroid refractory graft-versus-host disease.

A Phase I/II Study to Determine the MTD and Safety of CC-4047 Administered in Conjunction With Cisplatin and Etoposide

The purpose of this study is to determine the maximum tolerated dose and safety of CC-4047 given in combination with cisplatin and etoposide in patients with extensive disease small cell l...

PubMed Articles [13553 Associated PubMed Articles listed on BioPortfolio]

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.

Prostate Cancer is the forth most common type of cancer. Prostate-specific membrane antigen (PSMA) is anchored in the cell membrane of prostate epithelial cells. PSMA is highly expressed on prostate e...

The Role of Testosterone Therapy in the Setting of Prostate Cancer.

The role of testosterone in the development of prostate cancer and the safety of testosterone therapy (TTh) after prostate cancer treatment, or in the setting of active surveillance, remains controver...

Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population.

Prostate cancer is one of the most commonly diagnosed malignancies among men in Western populations. Evidence reported in the literature suggests that zinc may be related to prostate cancer. In this s...

A paradigm shift for prostate cancer diagnostics.

The current praxis of diagnosing prostate cancer, with systematic prostate biopsies in men with raised serum prostate-specific antigen (PSA) levels, leads to considerable over-diagnosis and over-treat...

Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.

Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer. In the present study, we explored the anti-cancer effects of the synthetic cannab...

Medical and Biotech [MESH] Definitions

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.

Tumors or cancer of the PROSTATE.

More From BioPortfolio on "Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...


Searches Linking to this Trial